Canada backs reimbursement for Kisunla; Lilly faces a 340B data lawsuit and Missouri order while guiding 2026 revenue to ...

After a 57% run-up over the past 52 weeks, Eli Lilly (NYSE: LLY) shares are expensive. The stock is now trading at 47 times trailing earnings. That's more than double the price-to-earnings ratio of ...

The case is the latest in a series of challenges that Lilly and Novo have brought against companies providing compounded ...

Some of Eli Lilly’s products beyond its core therapeutic area are performing well. It also boasts a deep and diversified ...

Lilly also announced other multibillion-dollar manufacturing expansion projects near its Indianapolis headquarters earlier ...

Industry sources tell Sports Business Journal that Excel has snared the AOR assignment both for mega-pharma Eli Lilly (2025 ...

Eli Lilly’s revenue surged on strong tirzepatide demand, but pricing and patent risks loom. Click here to read an analysis of ...

Mounjaro and Zepbound just handed Lilly a blowout quarter, but falling realized drug prices and one-time revenue boosts that ...

Shares of Eli Lilly (LLY) gained 10.0% over October 29 and 30. The advance spanned the day the company raised its 2026 ...

Eli Lilly (LLY) delivered strong third-quarter revenue and core drug sales, and the company raised its revenue guidance, confirming business resilience and long-term investment value.